Bao-Li Chang

Title: The Innovative Contributions of Bao-Li Chang

Introduction

Bao-Li Chang is a prominent inventor based in Paoli, PA (US). She has made significant strides in the field of medical diagnostics, particularly in transplant medicine. Her work focuses on utilizing micro-ribonucleic acid (miRNA) to enhance the understanding and management of transplant rejection and immunosuppression therapy.

Latest Patents

Bao-Li Chang holds a patent for the "Use of micro-ribonucleic acid (miRNA) to diagnose transplant rejection and tolerance of immunosuppression therapy." This invention relates to the discovery that the expression levels of certain microRNAs can serve as a diagnostic signature to predict transplant outcomes in recipients. The methods described in her patent include diagnosing acute rejection, predicting the risk of acute cellular rejection (ACR), and assessing the likelihood of successful immunosuppression therapy dosage adjustments.

Career Highlights

Chang's career is marked by her dedication to advancing medical science through innovative research. Her work has the potential to significantly improve patient outcomes in transplant medicine. She is affiliated with the University of Pennsylvania, where she continues to contribute to the field through her research and inventions.

Collaborations

Some of her notable coworkers include Abraham Shaked and Brendan Keating. Their collaborative efforts enhance the research environment and contribute to the advancement of medical diagnostics.

Conclusion

Bao-Li Chang's contributions to the field of transplant medicine through her innovative patent demonstrate her commitment to improving patient care. Her work exemplifies the impact of research and innovation in addressing critical medical challenges.